Merck & Co., Inc. Surgery Drug Sugammadex To Be Denied FDA Approval

March 14, 2015 11:32 AM

13 0

Pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) expects its surgery drug sugammadex to be denied regulatory approval. The announcement was made on Friday evening after the US Food and Drug Administration (FDA) canceled an advisory committee’s meeting to review the drug’s efficacy. Merck has been asked to gather further data to establish the effectiveness of the drug.

Sugammadex is an injection meant to reverse the effects of rocuronium- or vecuronium-induced anesthesia.

Also read: Amazon Prime Has More Than 100 Million Members

Read more

To category page